PE20040067A1 - NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE - Google Patents
NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINEInfo
- Publication number
- PE20040067A1 PE20040067A1 PE2003000512A PE2003000512A PE20040067A1 PE 20040067 A1 PE20040067 A1 PE 20040067A1 PE 2003000512 A PE2003000512 A PE 2003000512A PE 2003000512 A PE2003000512 A PE 2003000512A PE 20040067 A1 PE20040067 A1 PE 20040067A1
- Authority
- PE
- Peru
- Prior art keywords
- crobenetine
- parenteral administration
- new formulation
- biii
- concentration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- ILVITZMPXQQPBD-OFAXGOBFSA-N crobenetine Chemical compound O([C@H](CN1[C@@H]2CC3=CC=CC=C3[C@@H](C2(C)C)CC1)C)CC1=CC=CC=C1 ILVITZMPXQQPBD-OFAXGOBFSA-N 0.000 title 1
- 229950005056 crobenetine Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000007911 parenteral administration Methods 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- VCCBCXVFGHTDQN-UODBTFMRSA-N BIII-890CL Chemical compound O([C@H](CN1[C@@H]2CC3=C(O)C=CC=C3[C@](C2(C)C)(C)CC1)C)CC1=CC=CC=C1 VCCBCXVFGHTDQN-UODBTFMRSA-N 0.000 abstract 1
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 102100025342 Voltage-dependent N-type calcium channel subunit alpha-1B Human genes 0.000 abstract 1
- 101710088658 Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 abstract 1
- 239000008351 acetate buffer Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
QUE COMPRENDE: i)MANITOL; Y, ii)BIII 890 O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES; Y, iii)UN TAMPON DE ACIDO ACETICO/ACETATO, QUE TIENE QUE TIENE UNA CONCENTRACION MOLAR ENTRE 0,05 Y 0,5 Y UN VALOR DE pH DE 3,8 A 5. DONDE, SE UTILIZA COMO SUSTANCIA ACTIVA EL HIDROCLORURO DE BIII 890 EN UNA CONCENTRACION DE 0,1 mg/ml A 3 mg/ml. LA COMPOSICION DESCRITA SE APLICA POR VIA PARENTERAL O INTRAVENOSA PARA EL TRATAMIENTO DE ACCIDENTE CEREBROVASCULARWHICH INCLUDES: i) MANNITOL; AND, ii) BIII 890 OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS; AND, iii) AN ACETIC ACID / ACETATE BUFFER, WHICH HAS A MOLAR CONCENTRATION BETWEEN 0.05 AND 0.5 AND A pH VALUE OF 3.8 TO 5. WHERE, BIII HYDROCHLORIDE IS USED AS THE ACTIVE SUBSTANCE 890 AT A CONCENTRATION OF 0.1 mg / ml TO 3 mg / ml. THE DESCRIBED COMPOSITION IS APPLIED BY THE PARENTERAL OR INTRAVENOUS ROUTE FOR THE TREATMENT OF CEREBROVASCULAR ACCIDENT
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223784A DE10223784A1 (en) | 2002-05-29 | 2002-05-29 | New formulation for parenteral administration of crobenetine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20040067A1 true PE20040067A1 (en) | 2004-03-30 |
Family
ID=29432394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000512A PE20040067A1 (en) | 2002-05-29 | 2003-05-27 | NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1511487A1 (en) |
| JP (1) | JP2005531573A (en) |
| AR (1) | AR040135A1 (en) |
| AU (1) | AU2003240699A1 (en) |
| CA (1) | CA2487153A1 (en) |
| DE (1) | DE10223784A1 (en) |
| PE (1) | PE20040067A1 (en) |
| TW (1) | TW200406205A (en) |
| UY (1) | UY27824A1 (en) |
| WO (1) | WO2003099280A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10223783A1 (en) * | 2002-05-29 | 2003-12-11 | Boehringer Ingelheim Pharma | New formulation for parenteral administration of a Na-channel blocker |
-
2002
- 2002-05-29 DE DE10223784A patent/DE10223784A1/en not_active Withdrawn
-
2003
- 2003-05-23 AU AU2003240699A patent/AU2003240699A1/en not_active Abandoned
- 2003-05-23 WO PCT/EP2003/005400 patent/WO2003099280A1/en not_active Ceased
- 2003-05-23 CA CA002487153A patent/CA2487153A1/en not_active Abandoned
- 2003-05-23 EP EP03730101A patent/EP1511487A1/en not_active Withdrawn
- 2003-05-23 JP JP2004506804A patent/JP2005531573A/en active Pending
- 2003-05-27 TW TW092114284A patent/TW200406205A/en unknown
- 2003-05-27 PE PE2003000512A patent/PE20040067A1/en not_active Application Discontinuation
- 2003-05-27 UY UY27824A patent/UY27824A1/en not_active Application Discontinuation
- 2003-05-28 AR ARP030101864A patent/AR040135A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE10223784A1 (en) | 2003-12-11 |
| WO2003099280A1 (en) | 2003-12-04 |
| AR040135A1 (en) | 2005-03-16 |
| EP1511487A1 (en) | 2005-03-09 |
| UY27824A1 (en) | 2003-12-31 |
| CA2487153A1 (en) | 2003-12-04 |
| AU2003240699A1 (en) | 2003-12-12 |
| TW200406205A (en) | 2004-05-01 |
| JP2005531573A (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050066A1 (en) | PALONOSETRON LIQUID PHARMACEUTICAL FORMULATIONS | |
| PE20030399A1 (en) | FORMS OF ADMINISTRATION OF PROPIVERINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS WITH PROLONGED RELEASE OF THE ACTIVE SUBSTANCE | |
| BG107347A (en) | HIGH-CONCENTRATED STABLE SOLUTIONS OF MELOCYCAM | |
| PE20030575A1 (en) | STABLE AND HIGHLY CONCENTRATED MELOXICAM SOLUTIONS FOR NEEDLELESS INJECTION | |
| CY1114000T1 (en) | STABILIZED TERIPARATIDE SOLUTIONS | |
| GT199800113A (en) | ORAL PHARMACEUTICAL PREPARATION INCLUDING A COMPOUND OF ANTI-ULCER ACTIVITY AND PROCEDURE FOR ITS OBTAINING. | |
| BRPI0409185A (en) | topical anthelmintic veterinary formulations | |
| AR029373A1 (en) | METHOD FOR THE TREATMENT OF MIGRANES, USING SELECTIVE ANTAGONIST COMPOUNDS OF THE IGLUR5 RECEPTORS, USE OF SUCH SELECTIVE ANTAGONIST COMPOUNDS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF MIGRANES AND SAVINGS COMPOSED | |
| NO20062713L (en) | 2.6 bis-heteroaryl-4-aminopyrimidines as adenosine receptor antagonists | |
| PE20010053A1 (en) | AMOXICILLIN AND POTASSIUM CLAVULANATE FORMULATION | |
| PE20050822A1 (en) | FLORPHENICOL DERIVATIVES WITH BETTER SOLUBILITY IN WATER | |
| AR082049A1 (en) | LIQUID FORMULATIONS OF RUPATADINA FUMARATO | |
| PE20031044A1 (en) | DERIVATIVES OF PHENYLIMIDAZOLIDINE AND PREPARATION PROCESS | |
| ES2224917T1 (en) | PHARMACEUTICAL COMPOSITIONS OF FIBRINOLITIC AGENT. | |
| ATE367165T1 (en) | REEPITHELIALIZING PHARMACEUTICAL PREPARATIONS CONTAINING XANTHANG GUM | |
| DK1401405T3 (en) | Oral, pharmaceutical compositions with improved bioavailability | |
| AR031649A1 (en) | DRONEDARONA PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION | |
| PE20061437A1 (en) | COMPOSITION IN EMULSION INCLUDING DERIVATIVES OF CYCLOALKENE, STABLE IN ACID RANGE | |
| AR016382A1 (en) | USE OF A BENCIL-INDAZOL METOXIALCANOIC ACID DERIVATIVE. | |
| ES2028917T3 (en) | A PROCEDURE FOR PREPARING A STABLE INJECTABLE PHARMACEUTICAL COMPOSITION. | |
| BR0013283A (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient | |
| PE20040067A1 (en) | NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE | |
| ES2197781A1 (en) | Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen | |
| PE20011320A1 (en) | STABILIZED STEROID SUSPENSION | |
| PE20030092A1 (en) | FORMULATION OF AN INHALATION SOLUTION WITH A TIOTROPE SALT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |